Innate Pharma

IPHA

Market cap $168M

MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2026 Annual General Meeting.

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to Participate in the Jefferies Global Healthcare Conference.

Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call Transcript

Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung cancer.

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its business update and consolidated financial results for the quarter ending March 31, 2026. “We have continued to make solid progress across our priority clinical assets during the first quarter. We are approaching completion of enrollment in the Phase 1 dose escalation and backfill cohorts for IPH4502. In parallel, we have advanced the negotiati.

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 16, 2026.

MARSEILLE, France--(BUSINESS WIRE)---- $Innate #Biotech--Innate Pharma announces conference call and webcast for Q1 2026 Business Update.

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the D. Boral Capital Global Conference.

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer (NSCLC) will be presented in one of the Clinical Trials Plenary Sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22.

MARSEILLE, France--(BUSINESS WIRE)-- #Actionnaires--Innate Pharma to hold its annual general meeting of shareholders on May 21, 2026.